Inhibikase Therapeutics, Inc. (IKT) Balance Sheet
As of 2026-06-30 (10-Q), Inhibikase Therapeutics, Inc. (IKT) reported total assets of $163.6M, total liabilities of $10.3M and shareholders' equity of $153.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $31.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IKTInhibikase Therapeutics, Inc.Follow IKT — free
—
Price chart with a free account
- Market cap
- 221.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 40.8 | 7.2 | 9.2 | 56.5 | 139.2 | 31.2 | |
| Short-term investments | 0.0 | 15.9 | 4.1 | 41.1 | 39.5 | 127.8 | |
| Receivables | 0.1 | 0.0 | 0.0 | — | — | — | |
| Current assets | 42.5 | 24.4 | 14.2 | 98.5 | 180.1 | 162.3 | |
| Total assets | 42.5 | 24.9 | 14.5 | 98.6 | 181.2 | 163.6 | |
| Current liabilities | 4.1 | 3.7 | 3.4 | 3.7 | 8.3 | 10.3 | |
| Long-term debt | 0.2 | — | 0.4 | — | — | — | |
| Short-term debt | 0.0 | 0.1 | 0.2 | 0.1 | 0.0 | — | |
| Total liabilities | 4.1 | 3.9 | 3.5 | 3.7 | 8.3 | 10.3 | |
| Shareholders' equity | 38.4 | 21.0 | 11.0 | 94.9 | 172.9 | 153.3 |
USD millions · SEC XBRL
Inhibikase Therapeutics, Inc. — questions
- How much cash does Inhibikase Therapeutics, Inc. have?
- $31.2M in cash and cash equivalents as of 2026-06-30.
- What are Inhibikase Therapeutics, Inc.'s total assets?
- $163.6M as of 2026-06-30.
- What is Inhibikase Therapeutics, Inc.'s shareholders' equity?
- $153.3M as of 2026-06-30.
Every figure on this page comes from Inhibikase Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.